相似文献
1
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.
Cancer Sci. 2010 Mar;101(3):728-34. doi: 10.1111/j.1349-7006.2009.01449.x. Epub 2009 Nov 27.
2
Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.
J Biol Chem. 2015 Sep 18;290(38):22970-6. doi: 10.1074/jbc.C115.671123. Epub 2015 Aug 4.
3
Molecular mechanisms of resistance to antifolates, a review.
Acta Biochim Pol. 1995;42(4):457-64.
4
Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
Mol Ther. 2001 Jan;3(1):88-96. doi: 10.1006/mthe.2000.0236.
5
Stimulation of dihydrofolate reductase promoter activity by antimetabolic drugs.
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8572-6. doi: 10.1073/pnas.88.19.8572.
6
[Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Ai Zheng. 2002 Dec;21(12):1335-40.
7
Dihydrofolate reductase transcript level is not suitable for methotrexate-resistance prediction in choriocarcinoma cell line.
Int J Gynecol Cancer. 2010 Oct;20(7):1259-63. doi: 10.1111/igc.0b013e3181f05128.
8
Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S50-4.
9
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Mol Pharmacol. 2006 Aug;70(2):645-55. doi: 10.1124/mol.106.024505. Epub 2006 May 3.
10
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Ann Oncol. 2004 Jan;15(1):151-60. doi: 10.1093/annonc/mdh004.
引用本文的文献
1
Targeting CDK1 in cancer: mechanisms and implications.
NPJ Precis Oncol. 2023 Jun 13;7(1):58. doi: 10.1038/s41698-023-00407-7.
2
Isatin Counteracts Diethylnitrosamine/2-Acetylaminofluorene-Induced Hepatocarcinogenesis in Male Wistar Rats by Upregulating Anti-Inflammatory, Antioxidant, and Detoxification Pathways.
Antioxidants (Basel). 2022 Apr 1;11(4):699. doi: 10.3390/antiox11040699.
3
Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.
Exp Mol Med. 2021 Sep;53(9):1344-1355. doi: 10.1038/s12276-021-00668-x. Epub 2021 Sep 14.
4
The Metabolic Profiles in Hematological Malignancies.
Indian J Hematol Blood Transfus. 2019 Oct;35(4):625-634. doi: 10.1007/s12288-019-01107-8. Epub 2019 Apr 23.
5
Disparate Response to Methotrexate in Stem Versus Non-Stem Cells.
Stem Cell Rev Rep. 2016 Jun;12(3):340-51. doi: 10.1007/s12015-016-9645-9.
6
Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines.
J Orthop Surg Res. 2015 Sep 4;10:136. doi: 10.1186/s13018-015-0275-8.
本文引用的文献
1
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Blood. 2009 Mar 19;113(12):2637-45. doi: 10.1182/blood-2008-07-168583. Epub 2008 Nov 3.
2
CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Int J Oncol. 2008 May;32(5):1105-10.
3
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Cancer Sci. 2007 Sep;98(9):1417-23. doi: 10.1111/j.1349-7006.2007.00559.x. Epub 2007 Jul 23.
4
5
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
Cancer Chemother Pharmacol. 2007 Sep;60(4):479-88. doi: 10.1007/s00280-006-0387-2. Epub 2006 Dec 2.
6
15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Mol Cancer Ther. 2006 Jul;5(7):1827-35. doi: 10.1158/1535-7163.MCT-06-0023.
7
Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
Carcinogenesis. 2006 Sep;27(9):1768-77. doi: 10.1093/carcin/bgl015. Epub 2006 Mar 29.
8
Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Prog Drug Res. 2005;63:183-206. doi: 10.1007/3-7643-7414-4_8.
9
Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells.
Oncogene. 2005 Nov 3;24(48):7180-9. doi: 10.1038/sj.onc.1208874.
10
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Curr Opin Pharmacol. 2005 Aug;5(4):366-73. doi: 10.1016/j.coph.2005.04.009.
Zotero 插件